With Millipore® CTDMO Services, we offer everything you expect and more. Integrated expertise in contract testing, development, and manufacturing designed to accelerate your success.
Designed to support clients seeking a single partner who can leverage technical leadership, we provide a streamlined experience that covers the entire value chain from pre-clinical to commercial.
We are united with our clients around a single goal, to help patients, by forging partnerships aimed at bringing their pioneering breakthroughs to life.
Our contract testing services are integrated into the modality services to further streamline their development path. Our expertise, speed and agility is what makes the difference for your innovations.
We leverage 30+ years of global success working with drug development, material science and process technology aligned with our supply network to accelerate your program. We are the industry’s experienced choice, built to serve pioneers.
Monoclonal Antibodies (mAbs) have matured to become a core therapeutic modality, with more than 128 mAbs now approved for a wide range of diseases. Our highly experienced experts will help you to optimize, scale, and validate your manufacturing process to get you to late clinical and commercial success
Antibody-drug conjugates (ADC), known as “magic bullets”, have ignited a new era of targeted cancer therapy. With more than 35 years of experience, we are a leading expert in the conjugation of highly active molecules to monoclonal antibodies for the development and manufacture of ADCs.
Highly potent APIs (HPAPIs) are a powerful component in the treatment of diseases such as cancer. As one of the industry’s largest global manufacturers of HPAPIs, we have over 30 years of experience in the development and production of these complex, multi-step compounds.
Viral vectors (VVs) are used to deliver novel genetic material to cells advancing the potential to treat a wide range of diseases. With more than 25+ years of contract manufacturing experience, we have produced over 1,000 batches of virus to support gene therapy development from clinical through commercialization.
mRNA technology uses non-viral delivery systems and offers a great deal of versatility. As naked mRNA is unstable, drug delivery systems, such as lipid nanoparticles, are necessary to deliver mRNA to target cells. Our integrated CDMO capabilities include the development and manufacture of custom mRNAs and formulation of lipid nanoparticles (LNP).
To continue reading please sign in or create an account.Don't Have An Account?